Skip to main content

Table 2 Progression-free survival (PFS) outcomes for previously-treated patients with advanced MCC after treatment with avelumab (anti-PD-L1) compared with PFS rates from previous chemotherapy trials (historical controls)

From: Immunotherapy for Merkel cell carcinoma: a turning point in patient care

Anti-neoplastic agent(s)

Median PFS, months (95% CI)

PFS rate at 12 months, % (95% CI)

Reference

Avelumab (N = 88)

2.7 (1.4–6.9)

30 (21–41)

[39]

Cowey 2017 (n = 20)

2.1 (1.0–3.2)

0

[42]

Becker 2016 (n = 34)

3.0 (2.6–3.1)

0

[43]

Iyer 2016 (n = 30)

2.0 (NA [range: 0.4–11.6])

0*

[14]

  1. The most common second-line chemotherapy was topotecan. NA, not available; *based on PFS range (11–354 days) and Kaplan-Meier PFS estimates